LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy

Proteomics

Volumn 13, Issue 1, 2013, Pages 142-152

  Surin, Brigitte ^a,b   Sachon, Emmanuelle ^c,d   Rougier, Jean Philippe ^e   Steverlynck, Céline ^a   Garreau, Christelle ^a   Lelongt, Brigitte ^a,b   Ronco, Pierre ^a,b,e   Piedagnel, Rémi ^a,b  

^a Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Radiation Oncology Department   (France)

^d CNRS   (France)

^e HÔPITAL TENON   (France)

Author keywords

Biomedicine; Glomerular disease; IgA nephropathy; Kidney; Two dimensional gel electrophoresis

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ALPHA1 BETA GLYCOPROTEIN; ALPHA1 GLYCOPROTEIN; BIOLOGICAL MARKER; LAMININ; LAMININ G LIKE 3 FRAGMENT OF ENDOREPELLIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIDIMENSIONAL ELECTROPHORESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE SEVERITY; ELECTROPHORESIS; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; URINE LEVEL; WESTERN BLOTTING;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84872389165     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200267     Document Type: Article

References (57)

1. Berger, J., Hinglais, N., Les depôts intercapillaires d'IgA-IgG. J. Urol. Nephrol. (Paris) 1968, 74, 694-700.
2. Tomino, Y., Sakai, H., Miura, M., Endoh, M., Nomoto, Y., Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. Clin. Exp. Immunol. 1982, 49, 419-425.
3. Barrat, J., Feehally, J., IgA nephropathy. J. Am. Soc. Nephrol. 2005, 16, 2088-2097.
4. DAmico, G., Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin. Nephrol. 2004, 24, 179-196.
5. Julian, B., Wittke, S., Novak, J., Good, D. et al., Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007, 28, 4469-4483.
6. González-Buitrago, J., Ferreira, L., Lorenzo, I., Urinary proteomics. Clin. Chim. Acta 2007, 375, 49-56.
7. Thongboonkerd, V., Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin. Appl. 2008, 2, 1413-1421.
8. Knepper, M., Proteomics and the kidney. J. Am. Soc. Nephrol. 2002, 13, 1398-1408.
9. Park, M., Wang, E., Jin, D., Cha, J. et al., Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 2006, 6, 1066-1076.
10. Yokota, H., Hiramoto, M., Okada, H., Kanno, Y. et al., Absence of increased alpha1-microglobulin in IgA nephropathy proteinuria. Mol. Cell. Proteomics 2007, 6, 738-744.
11. Rocchetti, M., Centra, M., Papale, M., Bortone, G. et al., Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 2008, 8, 206-216.
12. Moon, P., Lee, J., You, S., Kim, T. et al., Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 2011, 11, 2459-2475.
13. Haubitz, M., Wittke, S., Weissinger, E., Walden, M. et al., Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005, 67, 2313-2320.
14. Wu, J., Wang, N., Wang, J., Xie, Y. et al., Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun. Mass Spectrom 2010, 24, 1971-1978.
15. Rabilloud, T., Silver staining of 2-D electrophoresis gels. Methods Mol. Biol. 1999, 112, 297-305.
16. Rabilloud, T., Detecting proteins separated by 2-D gel electrophoresis. Anal. Chem. 2000, 72, 48A-55A.
17. Gobom, J., Nordhoff, E., Mirgorodskaya, E., Ekman, R. et al., Sample purification and preparation technique based on nano-scale reversed-phase columns for the sensitive analysis of complex peptide mixtures by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 1999, 34, 105-116.
18. Shweke, N., Boulos, N., Jouanneau, C., Vandermeersch, S. et al., Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am. J. Pathol. 2008, 173, 631-642.
19. Mongiat, M., Sweeney, S., San Antonio, J., Fu, J. et al., Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278, 4238-4249.
20. Candiano, G., Musante, L., Bruschi, M., Petretto, A. et al., Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J. Am. Soc. Nephrol. 2006, 17, 3139-3148.
21. Magistroni, R., Ligabue, G., Lupo, V., Furci, L. et al., Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin. Nephrol. Dial. Transplant 2009, 24, 1672-1681.
22. Decramer, S., Gonzalez de Peredo, A., Breuil, B., Mischak, H. et al., Urine in clinical proteomics. Mol. Cell Proteomics 2008, 7, 1850-1862.
23. Kwak, N., Wang, E., Heo, I., Jin, D. et al., Proteomic analysis of alpha-1-antitrypsin in immunoglobulin A nephropathy. Proteomics Clin. Appl. 2007, 1, 420-428.
24. Carrell, R., alpha 1-antitrypsin: molecular pathology, leukocytes, and tissue damage. J. Clin. Invest. 1986, 78, 1427-1431.
25. Khan, T., Sinniah, R., Renal tubular antiproteinase (alpha-1-antitrypsin and alpha-1-antichymotrypsin) response in tubulo-interstitial damage. Nephron 1993, 65, 232-239.
26. Baum, A., Pohl, M., Kreusch, S., Cumme, G. et al., Searching biomarker candidates in serum using multidimensional native chromatography. II Method evaluation with Alport syndrome and severe inflammation. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2008, 876, 31-40.
27. Udby, L., Sørensen, O., Pass, J., Johnsen, A. et al., Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma. Biochemistry 2004, 43, 12877-12886.
28. Ishioka N, Takahashi N, FW, P., Amino acid sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin supergene family. Proc. Natl. Acad. Sci. USA 1986, 83, 363-367.
29. Piyaphanee, N., Ma, Q., Kremen, O., Czech, K. et al., Discovery and initial validation of α-1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin. Appl. 2011, 5-6, 334-342.
30. Kreunin, P., Zhao J., Rosser, C, Urquidi, V. et al., Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 2007, 6, 2631-2639.
31. Gonzalez, E., Reed, C., Bix, G., Fu, J. et al., BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 2005, 280, 7080-7087.
32. Cailhier, J., Sirois, I., Laplante, P., Lepage, S. et al., Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J. Biol. Chem. 2008, 283, 27220-27229.
33. Chang, J., Kang, U., Kim, D., Yi, J. et al., Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin. Appl. 2008, 2, 23-32.
34. Vuadens, F., Benay, C., Crettaz, D., Gallot, D. et al., Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 2003, 3, 1521-1525.
35. Oda, O., Shinzato, T., Ohbayashi, K., Takai, I. et al., Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin. Chim. Acta 1996, 255, 119-132.
36. O'Riordan, E., Orlova, T., Mendelev, N., Patschan, D. et al., Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin. Appl. 2008, 2, 1025-1035.
37. Soulez, M., Pilon, E., Dieudé, M., Cardinal, H. et al., The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ. Res. 2012, 110, 94-104.
38. ORiordan, E., Orlova, T., Podust, V., Chander, P. et al., Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am. J. Transplant. 2007, 7, 930-940.
39. Lerman, L., Chade, A., Angiogenesis in the kidney: a new therapeutic target? Curr. Opin. Nephrol. Hypertens. 2009, 18, 160-165.
40. Woodall, B., Nyström, A., Iozzo, R., Eble, J. et al., Integrin α2β1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283, 2335-2343.
41. Goyal, A., Pal, N., Concannon, M., Paul, M. et al., Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 2011, 286, 25947-25962.
42. Bix, G., Fu, J., Gonzalez, E., Macro, L., et al., Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α-2-β-1 integrin. J. Cell Biol. 2004, 166, 97-109.
43. Tashiro, K., Kodera, S., Takahashi, Y., Horikoshi, S. et al., Detection of apoptotic cells in glomeruli of patients with IgA nephropathy. Nephron 1998, 79, 21-27.
44. Wang, C., Peng, H., Tang, H., Liu, X. et al., Serum IgA1 from IgA nephropathy patients induces apoptosis in podocytes through direct and indirect pathways. Clin. Invest. Med. 2007, 30, E240-E249.
45. Chihara, Y., Ono, H., Ishimitsu, T., Ono, Y. et al., Roles of TGF-beta1 and apoptosis in the progression of glomerulosclerosis in human IgA nephropathy. Clin. Nephrol. 2006, 65, 385-392.
46. Qiu, L. Q., Sinniah, R., Hsu, S., Coupled induction of iNOS and p53 upregulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgA nephropathy. J. Am. Soc. Nephrol. 2004, 15, 2066-2078.
47. Aviezer, D., Hecht, D., Safran, M., Eisinger, M. et al., Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79, 1005-1013.
48. Zoeller, J., Iozzo, R., Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci. 2008, 6, 7.
49. Ebefors, K., Granqvist, A., Ingelsten, M., Mölne, J. et al., Role of glomerular proteoglycans in IgA nephropathy. PLoS One 2011, 6, e18575.
50. Laplante, P., Raymond, M., Gagnon, G., Vigneault, N. et al., Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J. Immunol. 2005, 174, 5740-5749.
51. Laplante, P., Raymond, M., Labelle, A., Abe, J. et al., Perlecan proteolysis induces an α-2-β-1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J. Biol. Chem. 2006, 281, 30383-30392.
52. Raymond, M., Désormeaux, A., Laplante, P., Vigneaul, t. N. et al., Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC. FASEB J. 2004, 18, 705-707.
53. Soulez, M., Sirois, I., Brassard, N., Raymond, M. et al., Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells 2010, 28, 810-820.
54. Sterk, L., de Melker, A., Kramer, D., Kuikman, I. et al., Glomerular extracellular matrix components and integrins. Cell Adhes. Commun. 1998, 5, 177-192.
55. Al-Ahmad, A., Lee, B., Saini, M., Bix, G., Perlecan domain V modulates astrogliosis in vitro and after focal cerebral ischemia through multiple receptors and increased nerve growth factor release. Glia 2011, 59, 1822-1840.
56. Talts, J., Andac, Z., Göhring, W., Brancaccio, A. et al., Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 1999, 18, 863-870.
57. Wagrowska-Danilewicz, M., Danilewicz, M., Expression of alpha5beta1 and alpha6beta1 integrins in IgA nephropathy (IgAN) with mild and severe proteinuria. An immunohistochemical study. Int. Urol. Nephrol. 2004, 36, 81-87.